Gilead's Kite Revealed New Data On Yescarta And Tecartus Outpatient Administration At EHA 2024
Gilead's Kite Revealed New Data On Yescarta And Tecartus Outpatient Administration At EHA 2024
吉利德的Kite公司在EHA 2024上公佈了Yescarta和Tecartus的門診管理新數據
– Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment –
分析顯示,對於復發/難治性大B細胞淋巴瘤,二線治療中使用Yescarta的製造可以縮短從白細胞分離到輸注的時間,相比三線及以上的治療。
– Data Builds on Previous Evidence on the Association Between Timely Infusion and Patient Outcomes –
這些數據在以往及時輸注與患者結局之間關聯關係的證據基礎上進行了補充。
– Preliminary Results Supporting Safety and Feasibility of Outpatient
初步結果支持門診的安全性和可行性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。